New drug aims to shield vulnerable transplant patients from dangerous gut bacteria
Disease control
Recruiting now
This study is testing a new oral drug, SNIPR001, in patients with blood cancers who are getting a stem cell transplant. The goal is to see if it can safely prevent dangerous, antibiotic-resistant E. coli infections in the gut when given alongside standard antibiotic prevention. R…
Phase: PHASE1, PHASE2 • Sponsor: SNIPR Biome Aps. • Aim: Disease control
Last updated Apr 02, 2026 06:42 UTC